Arvinas' Data From Phase 1 Trial Of Arv-102, Demonstrates Approximately 50% Or Greater Reduction Of LRRK2 In Cerebrospinal Fluid At All Doses By Day 14 And Maintaining The Reduction Through Day 28 In Parkinson's Disease Patients

Arvinas reported positive results from a Phase 1 trial of ARV-102, showing approximately a 50% or greater reduction of LRRK2 in cerebrospinal fluid in Parkinson's disease patients by day 14, with maintained reductions through day 28. The treatment also reduced endolysosomal and neuroinflammatory biomarkers associated with Parkinson's disease and was well tolerated at all dose levels. The data supports further development of ARV-102 for other neurodegenerative diseases characterized by lysosomal dysfunction.